CD19 and myeloid sarcoma: 4 target pathways were obtained by analyzing CD19+ B cell transcriptome data from MS patients without treatment and CD19+ B cell transcriptome data before and after Fingolimod treatment, and no target genes were obtained, suggesting that Fingolimod treatment in MS has less effect on B cells.